Mohammed Elmourtada Abdulgayoom: Exploring Hyperbaric Oxygen Therapy in Sickle Cell Disease
Mohammed Elmourtada Abdulgayoom, Clinical Hematology Specialist at Hamad Medical Corporation, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Hemoglobin, adding։
“I am pleased to share our newly published narrative review in Hemoglobin: Hyperbaric Oxygen Therapy in Sickle Cell Disease: A Narrative Review of Mechanisms, Clinical Applications, and Future Directions.
In this review, we explored the biological rationale and current clinical evidence for hyperbaric oxygen therapy (HBOT) as a potential adjunctive approach in selected complications of sickle cell disease, including vaso-occlusive pain, avascular necrosis, chronic leg ulcers, ophthalmic ischemia, and priapism.
While HBOT may improve tissue oxygenation and potentially reduce ischemia–reperfusion injury, the available evidence remains limited to case reports, small series, and early-phase studies.
Therefore, its role should currently be viewed as investigational and complementary to standard multidisciplinary care, rather than a routine treatment.
Further prospective and controlled studies are needed to define the patients most likely to benefit, optimal treatment protocols, and safety considerations in sickle cell disease.
Grateful to my co-authors for their valuable contributions: Awni Alshurafa, Jamil R Wafi, Tarek Abouzeid, Jaffer Altooq, and Mohamed A. Yassin.”
Title: Hyperbaric Oxygen Therapy in Sickle Cell Disease: A Narrative Review of Mechanisms, Clinical Applications, and Future Directions
Authors: Awni Alshurafa, Mohammed Abdulgayoom, Jamil R Wafi, Tarek Abouzeid, Jaffer Altooq,Mohamed A. Yassin
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials